Wenxiu Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Wenxiu Zhang has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
Dazheng Li
Department of Urology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Jinan, Shandong Province, China
1 shared publicationJianning Wang
Department of Urology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Jinan, Shandong Province, China
1 shared publication- Na Li
Mass Spectrometry Research Institute, Beijing Gobroad Hospital, Beijing, China
1 shared publication - Tianyi Wang
Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, China
1 shared publication - Wenzhi Du
Department of Urology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Jinan, China; Medical Integration and Practice Center, Shandong University, Jinan, Shandong, 17 250012 China
1 shared publication - Yong Zeng
Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University
1 shared publication
Latest Publications
- Open Access
- 22 May 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (21) , e48919
Unveiling novel drug targets for atherosclerosis: A Mendelian randomization analysis
Atherosclerosis is a leading cause of cardiovascular diseases, necessitating the identification of novel therapeutic targets. By utilizing Mendelian randomization, the aim is to identify potential drug targets for the treatment of atherosclerosis. Using results from genomewide association studies and protein quantitative trait loci data, we genetically identified causal effects of levels of several circulating proteins on atherosclerosis risk, validated using multiple statistical approaches, and identified promising drug targets. These findings demonstrated promising targets worthy of further clinical study, especially lipoprotein (a) and proprotein convertase subtilisin/kexin type 9.
- 22 May 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (21) , e48919
Open AccessUnveiling novel drug targets for atherosclerosis: A Mendelian randomization analysis
Atherosclerosis is a leading cause of cardiovascular diseases, necessitating the identification of novel therapeutic targets. By utilizing Mendelian randomization, the aim is to identify potential drug targets for the treatment of atherosclerosis. Using results from genomewide association studies and protein quantitative trait loci data, we genetically identified causal effects of levels of several circulating proteins on atherosclerosis risk, validated using multiple statistical approaches, and identified promising drug targets. These findings demonstrated promising targets worthy of further clinical study, especially lipoprotein (a) and proprotein convertase subtilisin/kexin type 9.